Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma

Human Pathology

Volumn 44, Issue 2, 2013, Pages 226-236

  Kim, Seok Hyung ^a   Chau, Gia Cac ^a   Jang, Young Hoon ^a   Lee, Seung Im ^a   Pyo, Suhkneung ^b   Um, Sung Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Esophageal squamous cell carcinoma; Mammalian target of rapamycin; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN PHOSPHORYLATION;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CYCLIN D1; DISEASE PROGRESSION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872676411     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.05.011     Document Type: Article

References (26)

1. P.C. Enzinger, and R.J. Mayer Esophageal cancer N Engl J Med 349 2003 2241 2252 (Pubitemid 37485141)
2. W.J. Blot, and J.K. McLaughlin The changing epidemiology of esophageal cancer Semin Oncol 26 1999 2 8 (Pubitemid 29529530)
3. C.O. Sung, S.Y. Han, and S.H. Kim Low expression of claudin-4 is associated with poor prognosis in esophageal squamous cell carcinoma Ann Surg Oncol 18 2011 273 281
4. K.W. Lee, J.H. Kim, and S. Han Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition Ann Surg Oncol 19 2012 326 335
5. R. Zoncu, A. Efeyan, and D.M. Sabatini mTOR: from growth signal integration to cancer, diabetes and ageing Nat Rev Mol Cell Biol 12 2011 21 35
6. S.H. Um, F. Frigerio, and M. Watanabe Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity Nature 431 2004 200 205 (Pubitemid 39243474)
7. S.H. Um, D. D'Alessio, and G. Thomas Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1 Cell Metab 3 2006 393 402 (Pubitemid 43811780)
8. K. Kim, S. Pyo, and S.H. Um S6K2 deficiency enhances ketone body production and increases PPARalpha activity in the liver Hepatology 55 2012 1727 1737
9. D. Benjamin, M. Colombi, C. Moroni, and M.N. Hall Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discov 10 2011 868 880
10. K. Inoki, M.N. Corradetti, and K.L. Guan Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 37 2005 19 24 (Pubitemid 40070934)
11. D. Liu, Y. Huang, and B. Chen Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma Cancer 117 2011 3763 3773
12. H.A. Lane, and M. Breuleux Optimal targeting of the mTORC1 kinase in human cancer Curr Opin Cell Biol 21 2009 219 229
13. Z.G. Wang, T. Fukazawa, and T. Nishikawa RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer Oncol Rep 23 2010 1167 1172
14. G. Hou, L. Xue, and Z. Lu An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR Cancer Lett 253 2007 236 248 (Pubitemid 47017539)
15. F.A. Sinicrope, S.B. Ruan, and K.R. Cleary bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis Cancer Res 55 1995 237 241
16. B.T. Nave, M. Ouwens, D.J. Withers, D.R. Alessi, and P.R. Shepherd Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation Biochem J 344 Pt 2 1999 427 431 (Pubitemid 30011599)
17. T. Kobayashi, M. Teruya, and T. Kishiki Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma Surgery 144 2008 729 735
18. S. Mega, M. Miyamoto, and Y. Ebihara Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma Dis Esophagus 18 2005 109 113 (Pubitemid 40975423)
19. L. Liu, L. Chen, J. Chung, and S. Huang Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins Oncogene 27 2008 4998 5010
20. K. Hirashima, Y. Baba, and M. Watanabe Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma Ann Surg Oncol 17 2010 2486 2493
21. J. Boone, F.J. Ten Kate, and G.J. Offerhaus mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol 61 2008 909 913
22. C. Espeillac, C. Mitchell, and S. Celton-Morizur S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy J Clin Invest 121 2011 2821 2832
23. S. Hashemolhosseini, Y. Nagamine, and S.J. Morley Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability J Biol Chem 273 1998 14424 14429 (Pubitemid 28319162)
24. X.M. Ma, S.O. Yoon, C.J. Richardson, K. Julich, and J. Blenis SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs Cell 133 2008 303 313 (Pubitemid 351508301)
25. P. Gulhati, K.A. Bowen, and J. Liu mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways Cancer Res 71 2011 3246 3256
26. M.A. Hildebrandt, H. Yang, and M.C. Hung Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy J Clin Oncol 27 2009 857 871